Development of new hetero-steroid hybrids with antiproliferative activity against MCF-7 breast cancer cells

Abstract

Abstract In continuation of our efforts to develop new antiproliferative agents that could be effective and selective in treatment of cancer, we designed and synthesized new hybrid structures containing an arylsulfonamide scaffold linked to a steroidal skeleton through a 1,2,3-triazole ring. Both in vitro cytotoxicity on breast MCF-7 cancer cells and human placental aromatase enzyme (pAROM) inhibition assays were performed on new hybrids. All new hybrids showed marked cytotoxic activity against breast MCF-7 cancer cells (IC 50 \u2009=\u20093.56–43.76\xa0μM) in comparison to staurosporine (IC 50 \u2009=\u20094.06\xa0μM). Tumor selectivity index was higher for some of the new hybrids on normal fibroblast (F-180) cells (TS\u2009=\u20091.5–25) in comparison to staurosporine (TS\u2009=\u20092.5). The p -nitro derivative exhibited the best inhibitory activity on the pAROM with an IC 50 of 64.6\xa0ng/cm 3 , compared to hybrids unsubstituted derivative, p -bromo derivative, and letrozole (IC 50 \u2009=\u2009375.14, 269.86, and 132.86\xa0ng/cm 3 , respectively). Furthermore, the p -nitro hybrid arrested the cell cycle selectively at the G2/M phase, in addition to inducing both early and late apoptotic processes of breast MCF-7 cancer cells. Molecular docking studies were performed within pAROM to explore the binding modes of the new hybrids. Collectively, the antiproliferative profile of new hybrids indicates how good they are as promising leads for developing tumor-specific cytotoxins, and deserve further studies to optimize their structure and in vivo activity. Graphic abstract